Research output per year
Research output per year
Personal profile
Biography
Dr Lim Wei Meng is a Malaysian registered pharmacist, currently a lecturer in School of Pharmacy, Monash University Malaysia. In 2008, he graduated with Master of Pharmacy from University of Strathclyde. Later, he worked as a pharmacist at Sarawak General Hospital for 2 years. Having a strong passion in teaching and research, he decided to join the academia. He joined International Medical University from year 2010 to 2022, and Monash University Malaysia in april 2022. He received Master of Science in Medical and Health Science in year 2014, and PhD in Medical and Health Sciences in year 2019. He involved extensively in cancer research, mainly focus on functional genomic and drug discovery.
Research interests
Drug Discovery
Dr Lim work involves the in vitro screening of new compounds using cancer cell lines to evaluate the potency and selectivity of the compounds. The compounds of interest will be investigated to understand the mechanism of action and pathways involved in the regulation of cancer cell survival.
Cancer biology and therapeutics
Dr Lim primary focus is to identify potential therapeutic target for endometrial cancer and pancreatic cancer. The research activities include high-throuput screening, drug repuposing, drug combination studies and immuno-oncology.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Master of Science, Universiti Perubatan Antarabangsa (International Medical University)
PhD, Universiti Perubatan Antarabangsa (International Medical University)
Master of Pharmacy, University of Strathclyde
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Functional roles of JNK and p38 MAPK signaling in nasopharyngeal carcinoma
Pua, L. J. W., Mai, C-W., Chung, F. F-L., Khoo, A. S-B., Leong, C-O., Lim, W-M. & Hii, L-W., 1 Feb 2022, In: International Journal of Molecular Sciences. 23, 3, 18 p., 1108.Research output: Contribution to journal › Review Article › Research › peer-review
Open AccessFile25 Citations (Scopus) -
Parallel genome-wide RNAi screens identify lymphocyte-specific protein tyrosine kinase (LCK) as a targetable vulnerability of cell proliferation and chemoresistance in nasopharyngeal carcinoma
Liew, K., Yu, G. Q. S., Wei Pua, L. J., Wong, L. Z., Tham, S. Y., Hii, L-W., Lim, W-M., OuYong, B. M., Looi, C. K., Mai, C-W., Fei-Lei Chung, F., Tan, L. P., Ahmad, M., Soo-Beng Khoo, A. & Leong, C-O., 28 Apr 2021, In: Cancer Letters. 504, p. 81-90 10 p.Research output: Contribution to journal › Article › Research › peer-review
7 Citations (Scopus) -
RNAi-based combination therapies
Karim, S., Lim, W. M., Zeeshan, F., Alkreathy, H. M., Alhakamy, N. A., Aldawsari, H. M. & Md, S., 2021, Nanocarriers for the Delivery of Combination Drugs. Baboota, S. & Ali, J. (eds.). Netherlands: Elsevier, p. 307-335 29 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Research › peer-review
-
Antibacterial activity and mode of action of β-caryophyllene on Bacillus cereus
Moo, C-L., Yang, S-K., Osman, M-A., Yuswan, M. H., Loh, J-Y., Lim, W-M., Lim, S-H-E. & Lai, K-S., Mar 2020, In: Polish Journal of Microbiology. 69, 1, p. 49-54 6 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile47 Citations (Scopus) -
Molecular hybrids integrated with benzimidazole and pyrazole structural motifs: design, synthesis, biological evaluation, and molecular docking studies
Sivaramakarthikeyan, R., Iniyaval, S., Saravanan, V., Lim, W-M., Mai, C-W. & Ramalingan, C., 5 May 2020, In: ACS Omega. 5, 17, p. 10089-10098 10 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile30 Citations (Scopus)